NYC, May 24, 2025 (GLOBE NEWSWIRE) — NEW YORK, May 24, 2025 / GlobeNewswire/ — ...

Vigil Neuroscience Inc ( ($VIGL) ) just unveiled an announcement. On May 22, 2025, Vigil Neuroscience, Inc. held its Annual Meeting of ...

Sanofi is acquiring Vigil Neuroscience, a biotech firm focused on novel neurodegenerative disease therapies, to boost its ...

About a year after investing in Vigil Neuroscience Inc., Sanofi is now acquiring the Watertown biotech and its treatment in ...

WASHINGTON-The Supreme Court on Thursday granted President Trump's emergency request to fire federal commissioners in the face of a law prohibiting their arbitrary removal, but went out of its way to ...

Here's a recap of the week’s most important stories.

Sanofi to acquire clinical-stage biotechnology company, Vigil Neuroscience for $470 million: Paris Friday, May 23, 2025, 11:00 Hrs [IST] Sanofi, an innovative global healthcare co ...

French pharma Sanofi has acquired the U.S.-based biotech firm Vigil Neuroscience for $470 million, aiming to bolster its ...

Fintel reports that on May 22, 2025, JMP Securities downgraded their outlook for Vigil Neuroscience (NasdaqGS:VIGL) from ...

Vigil Neuroscience (VIGL) and Sanofi (SNY) announced that it has entered into a definitive merger agreement pursuant to which ...

Sanofi SA made good on its plan to bear down on M&A by agreeing to buy Vigil Neuroscience Inc. for $8 per share (NASDAQ:VIGL). Included in the transaction is a non-tradeable contingent value right ...

Deal includes VG-3927, a first-in-class TREM2 agonist aimed at advancing next-generation Alzheimer disease therapies.